Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development

Author's Avatar
Feb 03, 2023

Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Development. Dr. Aung will assume all clinical development leadership responsibilities of Ambrx’s proprietary pipeline of several ADC product candidates.